Background: Coronavirus disease-2019 (COVID-19) has a wide range of pathophysiological effects. Curcumin, an active constituent of Curcuma longa (turmeric), has several properties, including anti-inflammatory, antioxidant, antiviral, anti-thrombotic, and anti-proliferative effects, which make it a promising candidate for the symptomatic treatment of COVID-19. Objective: We aimed to determine the effects of curcumin administered with piperine (to optimize absorption) on symptoms in patients with COVID-19 in a double-blind, randomized, controlled trial at a 30-bed dedicated COVID Health Center (DCHC) in Maharashtra, India. Methods: In addition to conventional COVID-19 treatment, patients in the control group received a dose of probiotics twice a day, and patients in the study group received curcumin (525 mg) with piperine (2.5 mg) in tablet form twice a day. The effects of curcumin/piperine treatment on primary and secondary outcomes were assessed for the duration of hospitalization. Results: Patients with mild, moderate, and severe symptoms who received curcumin/piperine treatment showed early symptomatic recovery (fever, cough, sore throat, and breathlessness), less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to patients of the control group. Furthermore, curcumin/piperine treatment appeared to reduce the duration of hospitalization in patients with moderate to severe symptoms, and fewer deaths were observed in the curcumin/piperine treatment group. Conclusions: Administration of oral curcumin with piperine as an adjuvant symptomatic therapy in COVID-19 treatment could substantially reduce morbidity and mortality, and ease the logistical and supply-related burdens on the healthcare system. Curcumin could be a safe and natural therapeutic option to prevent Post-Covid thromboembolic events. Clinicaltrials.gov identifier: CTRI/2020/05/025482
【저자키워드】 COVID-19, Curcumin, Anti-inflammatory, adjuvant therapy, Traditional medicine, post-covid thromboembolic episodes, 【초록키워드】 Treatment, therapy, Antiviral, India, Symptom, cough, antioxidant, Clinical outcome, COVID, oxygen saturation, Deterioration, symptomatic, Fever, Patient, death, Symptomatic treatment, Mild, morbidity and mortality, moderate, dose, Healthcare system, Safe, double-blind, therapeutic option, piperine, sore throat, Tablet, breathlessness, Thromboembolic events, control group, severe symptoms, treatment group, center, secondary outcome, randomized, controlled trial, Administered, Effect, duration of hospitalization, Effects, Prevent, addition, less, determine, maintain, reduce, severe symptom, Curcuma, pathophysiological, patients with COVID-19, patients with moderate, the study group, were assessed, 【제목키워드】 clinical, adjuvant, oral,